BioSpace News Archive

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today reported financial and corporate results for its first quarter ended March 31, 2023.

Merit Medical Systems, Inc., a leading global manufacturer and marketer of healthcare technology, announced it has completed the acquisition of a portfolio of dialysis catheter products and the BioSentry® Biopsy Tract Sealant System from AngioDynamics, Inc. for a total cash consideration of $100 million.

Elevation Oncology, Inc. announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase shares of common stock and of accompanying warrants to purchase shares of common stock.

AngioDynamics, Inc. announced that it has completed the sale of its Dialysis product portfolio and BioSentry Tract Sealant System Biopsy product to Merit Medical Systems, Inc. for $100 million in cash.

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved commercial production at the company’s newest cell therapy manufacturing facility in Devens, Massachusetts.

DBV Technologies, a clinical-stage biopharmaceutical company, announced upcoming participation in the European Academy of Allergy and Clinical Immunology Congress, June 9 – 11, 2023, in Hamburg, Germany.

The U.S. Food and Drug Administration Antimicrobial Drugs Advisory Committee voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants born during or entering their first RSV season.

Gusto Global, LLC announces an expansion of its partnership with the Crohn’s & Colitis Foundation to advance groundbreaking technical development for a prognostic linking predictive microbiome-based biomarkers to sustainable remission.

Revolution Medicines, Inc. announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Goldman Sachs 44th Annual Global Healthcare Conference and in Barclays’ ongoing series of virtual lunchtime fireside chats.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim analysis from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) versus an active comparator in IgA nephropathy (IgAN), at the 60th ERA Congress in Milan, Italy, June 15-18, 2023.